QuVa Pharma Recalls Norepinephrine Injection Bags Due to Incorrect Excipient
QuVa Pharma is recalling 168 bags of Norepinephrine Injection compounded in 5% Dextrose instead of 0.9% Sodium Chloride. The product was distributed in California.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which typically corresponds to a severity score of 1 or 2. Given the potential for clinical impact from an incorrect excipient in a compounded medication, a score of 2 (Moderate) is appropriate as it represents a minor labeling or formulation error that is unlikely to cause adverse health consequences but warrants precautionary action.
Plain-English summary
QuVa Pharma, Inc. is recalling 168 bags of Norepinephrine 8 mg (32 mcg/mL) added to 0.9% Sodium Chloride Injection 250 mL Bag. The recall is due to the product being compounded in 250 mL 5% Dextrose instead of the intended 0.9% Sodium Chloride solution.
The affected product is identified by Lot #10016014 with an expiration date of 01/06/2019. The product code is 70092-9035-05. The recall is classified as Class III by the FDA, indicating that use of or exposure to the product is not likely to cause adverse health consequences.
The product was distributed in California. Consumers and healthcare providers should stop using the affected product and contact QuVa Pharma or their healthcare provider for further instructions.
The recalled product
- Product
- Norepinephrine 8 mg (32 mcg/mL) added to 0.9% Sodium Chloride Injection 250 mL Bag, Rx only, Compounded by: QuVA Pharma 1075 West Park One Drive Suite 100 Sugar Land, TX 77478. Product Code 70092-9035-05
- Manufacturer
- QuVa Pharma, Inc.
- Category
- Drug — Compounded Medication
- Hazard
- Affected units
- 168
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot #:10016014 Exp. 01/06/2019
Distribution
Distributed in 1 state:
Related recalls
Same manufacturer · QuVa Pharma, Inc.
See all →- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- HighCompounded pain injection syringes recalled over presence of particulate matter
FDA (Drugs) · 2025-11-05
- HighCompounded Fentanyl and Bupivacaine Epidural Injections Recalled for Sterility Assurance
FDA (Drugs) · 2025-04-02
- HighCompounded Fentanyl-Bupivacaine Epidural Injections Recalled for Sterility Failure
FDA (Drugs) · 2025-04-02
- HighCompounded Fentanyl-Ropivacaine Epidural Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2025-04-02
Same hazard · incorrect excipient
See all →- ModerateTadalafil Tablets Recalled for Incorrect Product Formulation
FDA (Drugs) · 2021-11-17
- LowJubilant Cadista Recalls Valsartan Tablets Due to Potential Excipient Error
FDA (Drugs) · 2018-08-29
- LowJubilant Cadista Recalls Valsartan Tablets Due to Incorrect Excipient Grade
FDA (Drugs) · 2018-08-29
- ModerateJubilant Cadista Recalls Valsartan Tablets Due to Incorrect Excipient Grade
FDA (Drugs) · 2018-08-29
- LowJubilant Cadista Recalls Valsartan Tablets Due to Incorrect Excipient Size
FDA (Drugs) · 2018-06-13